A High-Density CHO-S Transient Transfection System

A high-density CHO-S transient transfection system is a mammalian protein expression platform that transfects CHO-S cells at a high viable-cell density to produce large amounts of recombinant protein without developing a stable cell line. ExpiCHO is the leading commercial example of this system and, for most tested proteins, can provide higher protein titers and more stable-CHO-like glycosylation than Expi293. However, Expi293 may still be the better choice when faster protein production or stronger expression of a particular molecule is required.

Mammalian protein expression is widely used for antibodies, cytokines, enzymes, receptors and other complex recombinant proteins that require correct folding, disulfide bond formation and post-translational modification. Historically, HEK293 cells dominated transient protein expression, while CHO cells were reserved mainly for stable cell line development and manufacturing. High-density CHO transient transfection has narrowed that gap by making milligram-to-gram recombinant protein production in CHO cells practical within a much shorter development timeline.

What Is a High-Density CHO-S Transient Transfection System?

A transient transfection system introduces plasmid DNA into mammalian cells without permanently integrating the expression construct into the cellular genome. The cells temporarily use that DNA to produce the target protein, enabling researchers to obtain material within days rather than completing the lengthy selection and screening required for a stable cell line. A CHO transient transfection system uses Chinese hamster ovary cells as the production host. In high-density workflows, cells are transfected at a substantially greater viable cell concentration than in conventional transient CHO processes. The higher number of productive cells per milliliter, combined with optimized expression media, transfection chemistry, enhancers and nutrient feeds, supports greater volumetric productivity.

High-density transfection is not simply about obtaining the highest transfection percentage. A culture with a slightly lower percentage of transfected cells can still achieve a higher protein titer when it contains significantly more viable and productive cells per milliliter.

What Is the CHO-S Cell Line?

The CHO-S cell line is a suspension-adapted CHO host suitable for serum-free cell culture and scalable recombinant protein production. ExpiCHO-S cells are a clonal derivative of the parental CHO-S cell line and are adapted to high-density suspension growth in chemically defined ExpiCHO Expression Medium.

According to the platform guide, ExpiCHO-S cells have an approximate doubling time of 17 hours and can reach densities near 20 × 10⁶ cells/mL in shake-flask culture. The cells are designed to support direct transfection in the same expression media without requiring a complete medium exchange.

This makes the CHO-S cell line particularly useful for projects that require:

• Antibodies and antibody fragments
• Bispecific and multispecific proteins
• Fc-fusion proteins
• Cytokines and growth factors
• Soluble receptor domains
• Recombinant enzymes
• Vaccine and diagnostic antigens

Why Compare CHO Cells With HEK293 Cells?

CHO cells are widely established hosts for producing biotherapeutic proteins through stable manufacturing processes. HEK293 cells, however, became the traditional choice for rapid transient expression because they are easy to transfect and can produce useful protein quantities in a short period. The host cell matters because CHO cells and HEK293 cells do not process every protein identically. Host-dependent differences may influence glycosylation, folding, aggregation, stability, enzyme activity and other critical quality attributes. These differences can become important when material produced during drug discovery is later replaced by protein manufactured from a stable CHO cell line.

Using CHO-derived material earlier in development can improve host continuity. It does not guarantee that transient and stable material will be identical. Still, it can reduce the risk of discovering major host-related differences after a candidate has entered advanced studies.

What Is the Expi293 System?

Expi293, sometimes written as expi293 in informal searches, is a high-density HEK293-based protein expression system. It combines suspension-adapted Expi293F cells, chemically defined Expi293 Expression Medium, a cationic lipid transfection reagent and specialized enhancers. Expi293F cells are derived from the 293F lineage and are optimized for suspension growth, high transfectability and rapid protein production. The system supports culture formats ranging from multiwell plates to large disposable bioreactors. The official guide reports that some antibody and non-antibody proteins can reach yields of up to approximately 1 g/L, although actual performance remains protein-dependent.

Expi293 is especially attractive for rapid construct screening, early reagent production and proteins that perform particularly well in a human-cell background.

How Does ExpiCHO Work?

ExpiCHO combines several coordinated components:

1. High-density ExpiCHO-S cells
2. Chemically defined, serum-free expression media
3. Plasmid DNA encoding the target protein
4. ExpiFectamine CHO transfection reagent
5. A post-transfection enhancer
6. A nutrient-rich culture feed
7. A protein-specific temperature and harvest strategy

The cells are commonly adjusted to approximately 6 × 10⁶ viable cells/mL for transfection. The official workflow permits approximately 0.5–1.0 µg plasmid DNA per milliliter of initial culture, with the selected protocol determining the feed schedule, temperature and final harvest window.

Unlike a conventional low-density CHO process, the entire system is designed to function as an integrated platform. Replacing the recommended medium, reagent or feed without optimization may reduce performance because the components are formulated to work together.

ExpiCHO vs Expi293: What Did the Comparative Study Find?

The landmark comparative study evaluated ExpiCHO against Expi293 and FreeStyle MAX CHO. Fourteen proteins representing multiple formats were expressed, including IgGs, bispecific antibodies, antibody fragments, cytokines, enzymes and fusion proteins. Transfections were performed at a 50 mL scale in 250 mL non-baffled shake flasks, using approximately 1 µg plasmid DNA per milliliter of culture. Protein titer, purified protein yield, transfection efficiency, monodispersity, biological activity and post-translational modifications were evaluated.

Protein Titer and Protein Yield

ExpiCHO produced higher expression than Expi293 for 13 of the 14 proteins tested, with reported titer increases ranging from approximately 2.1- to 12.5-fold for those proteins. Purified yields were also higher for most targets.

In the comparison with conventional FreeStyle MAX CHO:

• IgG 1 expression was approximately 70-fold higher in ExpiCHO.
• Cytokine 1 expression was approximately 57-fold higher in ExpiCHO.
• Compared with Expi293, the same proteins showed approximately 2.7-fold and 2-fold improvements, respectively.

These results demonstrate why ExpiCHO became an important platform for high-density CHO transient transfection. It made it possible to generate quantities of CHO-derived protein that had previously required extensive scale-up or early stable cell line development.

However, one fusion protein expressed more strongly in Expi293 than ExpiCHO. This is an important practical finding: no mammalian expression system performs best for every molecule. Protein sequence, folding complexity, secretion efficiency and host-specific processing can all affect the outcome.

Transfection Efficiency Versus Productive Cell Density

The study reported approximate transfection efficiencies of:

• 92% for Expi293F cells
• 79% for ExpiCHO-S cells
• 50% for FreeStyle CHO-S cells

Although the percentage was higher in Expi293, ExpiCHO was transfected at a much higher cell density. The estimated number of transfected cells per milliliter was therefore approximately 6.4 × 10⁶ in ExpiCHO compared with 3.4 × 10⁶ in Expi293.

This illustrates an essential principle: volumetric protein productivity depends on viable cell density, transfection efficiency, cell-specific productivity and the duration of productive expression—not on transfection percentage alone.

How Culture Duration and Temperature Affect Results

Expi293 is primarily designed for rapid protein production, with many proteins harvested within about five to seven days. ExpiCHO has a delayed but more prolonged expression profile, allowing protein to continue accumulating over an extended culture period. ExpiCHO offers three general workflow options.

Standard Protocol

The Standard Protocol uses enhancer and feed addition while maintaining the culture near 37°C. It provides a relatively fast workflow and can offer an effective balance between protein yield and product quality.

High-Titer Protocol

The High-Titer Protocol includes a temperature shift to approximately 32°C after transfection. Mild hypothermia can slow cell growth while extending viability and the productive phase of the culture.

Max-Titer Protocol

The Max-Titer Protocol combines a temperature shift with two feed additions and a longer culture duration. This can maximize accumulation for stable proteins, particularly antibodies that remain intact in the culture medium. The latest harvest does not automatically provide the best result. Extended culture can increase total titer while also increasing degradation, aggregation or altered glycan species for sensitive proteins. The best harvest should therefore be selected according to usable protein yield, not titer alone.

Protein Monodispersity, Aggregation and Degradation

Monodispersity describes how much of the purified sample exists in the desired molecular form rather than as aggregates or fragments. Size-exclusion chromatography is commonly used to measure monomer content, high-molecular-weight species and low-molecular-weight degradation products. In the comparative study, several ExpiCHO-produced proteins retained monodispersity similar to Expi293 material. Other proteins showed quality changes when the culture was extended to later harvest days.

One antibody achieved its best purified yield at an intermediate ExpiCHO harvest. Extending the culture further caused a notable reduction in recoverable yield and monomer content, along with the appearance of a degradation fragment. The practical lesson is positive and useful: ExpiCHO provides flexibility. Researchers can sample the culture at several time points and select the harvest that delivers the greatest amount of correctly assembled, active protein.

Glycosylation and Post-Translational Modifications

Glycosylation can influence folding, solubility, aggregation, receptor interactions, serum persistence and biological activity. Because glycan processing is host- and process-dependent, the same protein expressed in CHO cells and HEK293 cells may have different glycan distributions. The comparative study found that antibodies produced with ExpiCHO generally had glycosylation profiles more similar to stable CHO-derived antibodies than material produced in Expi293. Expi293 samples showed greater galactosylation for some antibodies, while extended low-temperature ExpiCHO culture increased certain high-mannose species.

A later study also found that transient ExpiCHO expression was delayed but prolonged relative to HEK293 expression. It reported strong antibody production and favorable aggregation characteristics, while showing that sialylation could remain protein- and process-dependent. Glycosyltransferase co-expression, media supplementation and harvest optimization are potential strategies when terminal sialylation is a critical quality attribute. Therefore, using the same host reduces one important source of variability, but culture temperature, nutrient conditions and harvest time must still be optimized.

Transient Expression Versus Stable Cell Line Development

A stable cell line contains an expression construct that has been integrated into the cellular genome and maintained during cell division. Developing such a line requires selection, clone screening, productivity testing, stability studies and process development.

Transient protein expression is much faster and supports:

• Construct and signal-peptide screening
• Candidate comparison
• Assay development
• Structural biology
• Early functional testing
• Pharmacokinetic studies
• In-vivo proof-of-concept studies
• Initial developability evaluation

ExpiCHO can therefore serve as a bridge between early research and stable CHO manufacturing. It enables drug discovery teams to work with CHO-derived material before investing in a permanent production clone. Transient ExpiCHO material should not be treated as an exact substitute for material from the final stable cell line. Clone selection, bioreactor conditions, media composition and downstream processing can continue to influence product quality. Nevertheless, early CHO alignment can make the transition more predictable.

Important Optimization Opportunities Beyond the Original Comparison

The original ExpiCHO–Expi293 comparison established the value of high-density CHO expression, but additional variables can further improve results.

Expression Vector Design

A strong protein expression system cannot fully compensate for an inefficient construct. Promoter choice, untranslated regions, codon usage, transcription termination and plasmid quality can affect transient expression. A recent review of mammalian transient gene expression identified cell-line selection, vector engineering, culture medium, transfection conditions and process optimization as major opportunities for improving recombinant protein production.

Signal-Peptide Selection

The best secretion signal is often protein-specific. Screening multiple signal peptides can significantly improve secretion without changing the protein’s mature amino-acid sequence. Research in CHO-derived hosts has demonstrated that matching a signal peptide to the target protein can improve transient expression and secreted yield.

Plasmid Quality

Plasmid DNA should be sterile, predominantly supercoiled and free from contaminants such as phenol and excessive salts. Poor plasmid quality can reduce transfection consistency and cell viability. The Expi293 guide specifically emphasizes clean, high-quality plasmid preparation, and the same principle applies to ExpiCHO workflows.

Scale-Down Before Scale-Up

Small-scale screening can compare constructs, chain ratios, signal peptides and harvest days before committing to a large culture. ExpiCHO can be used in deep-well plates, mini-bioreactor tubes and shake flasks, allowing high-throughput evaluation followed by direct scale-up.

Measure Usable Yield, Not Titer Alone

The most informative performance metric is the amount of purified, correctly assembled and biologically active protein recovered from a defined culture volume.

A strong evaluation should include:

• Culture titer
• Final purified yield
• Purification recovery
• Monomer percentage
• Aggregation and fragmentation
• Binding or enzyme activity
• Glycan profile where relevant
• Lot-to-lot reproducibility

ExpiCHO vs Expi293 Comparison

Best Transient Transfection System for Protein Expression

The best transient transfection system for protein expression depends on the target molecule and the purpose of the study.

Choose ExpiCHO when:

• The future manufacturing host is expected to be CHO.
• CHO-like post-translational processing is important.
• A high protein yield is needed for preclinical work.
• The protein remains stable during an extended culture.
• Host continuity is valuable for drug discovery.

Choose Expi293 when:

• Rapid turnaround is the highest priority.
• Many constructs must be screened quickly.
• A target expresses poorly in CHO cells.
• Human-cell processing is preferred for the application.
• A shorter and simpler culture workflow is required.

For a high-value or difficult-to-express protein, the strongest approach is often a small parallel comparison. Express the same construct in ExpiCHO and Expi293, then compare purified yield, monodispersity, activity and relevant post-translational modifications.

FAQs

Does ExpiCHO always produce more protein than Expi293?

No. ExpiCHO produced higher titers for most proteins in the major comparative study, but at least one tested fusion protein expressed more strongly in Expi293. Performance remains protein-specific.

Is ExpiCHO the same as a stable CHO cell line?

No. ExpiCHO is a transient system. It can produce CHO-derived material rapidly, while stable cell line development creates a permanent production clone for long-term manufacturing.

Why is high-density transfection beneficial?

It increases the number of potentially productive cells in each milliliter of culture. When combined with efficient transfection, appropriate feeding and extended viability, this can substantially improve volumetric protein titer.

What is the ideal ExpiCHO harvest day?

There is no universal harvest day. Stable proteins may benefit from extended High-Titer or Max-Titer cultivation, while sensitive proteins may achieve their best purified yield at an earlier or intermediate harvest.

Can ExpiCHO be used for proteins other than antibodies?

Yes. ExpiCHO has been used for antibodies, Fabs, bispecific proteins, cytokines, enzymes, fusion proteins, receptors and other secreted recombinant proteins.

Conclusion

A high-density CHO-S transient transfection system offers a powerful combination of speed, scalability and CHO host continuity. ExpiCHO has transformed transient recombinant protein production by enabling milligram-to-gram quantities of many proteins without waiting for stable cell line development.

Compared with Expi293, ExpiCHO often provides higher titers and protein attributes that more closely resemble stable CHO-derived material. Expi293 remains highly valuable for rapid expression and protein-specific HEK293 advantages. The strongest platform decision considers not only protein titer, but also purified yield, monodispersity, biological activity, glycosylation, development timeline and the intended manufacturing host. By optimizing cell health, vector design, signal peptide, expression media, feeding strategy, temperature and harvest timing, researchers can use either mammalian expression system to generate high-quality recombinant proteins efficiently and confidently.